From Barchart: 2025-06-06 15:00:00

Lucid Capital Markets has initiated coverage on atai Life Sciences N.V. (NASDAQ:ATAI) with a Buy rating and a $12 price target. The biotech firm is a leader in psychedelic-based mental health therapies, with a comprehensive pipeline of programs focusing on depression, anxiety, PTSD, and substance use disorders.

atai has built a strong portfolio with four psychedelic drug candidates, positioning itself at the forefront of innovation in a sector with decades of academic research. The firm’s investment in COMPASS Pathways, a key player in late-stage testing for treatment-resistant depression, further strengthens its strategy.

atai and its affiliates are involved in four of the twelve major depression-related psychedelic trials currently underway. With over 30 active or planned clinical programs involving psychedelics, Lucid sees significant upside potential in atai’s diversified and early-mover approach amidst growing demand for novel mental health solutions.



Read more at Barchart:: Lucid Launches Coverage on atai Life Sciences With…